Unknown

Dataset Information

0

Correction: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial

ABSTRACT:

SUBMITTER: Bergman M 

PROVIDER: S-EPMC9632073 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
| S-EPMC9229430 | biostudies-literature
Unknown Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.
| S-EPMC6889334 | biostudies-literature
Unknown Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis.
| S-EPMC3841743 | biostudies-literature
Unknown Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs.
| S-EPMC4162652 | biostudies-literature
Unknown Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis.
| S-EPMC9348611 | biostudies-literature
Unknown Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.
| S-EPMC6902348 | biostudies-literature
Unknown Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians.
| S-EPMC7211222 | biostudies-literature
Unknown Comparison of Biologic Disease-Modifying Antirheumatic Drug Therapy Persistence Between Biologics Among Rheumatoid Arthritis Patients Switching from Another Biologic.
| S-EPMC4883249 | biostudies-literature
Unknown Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia.
| S-EPMC9536792 | biostudies-literature
Unknown Overall survival in patients with rheumatoid arthritis and solid malignancies receiving biologic disease-modifying antirheumatic therapy.
| S-EPMC10556973 | biostudies-literature